A
216.47
-0.91 (-0.42%)
| Previous Close | 217.38 |
| Open | 216.08 |
| Volume | 730,318 |
| Avg. Volume (3M) | 708,578 |
| Market Cap | 11,139,495,936 |
| Price / Earnings (Forward) | 333.33 |
| Price / Sales | 15.90 |
| Price / Book | 210.80 |
| 52 Weeks Range | |
| Earnings Date | 3 Aug 2026 |
| Profit Margin | -64.39% |
| Operating Margin (TTM) | -45.67% |
| Diluted EPS (TTM) | -5.76 |
| Quarterly Revenue Growth (YOY) | 62.00% |
| Total Debt/Equity (MRQ) | 397.02% |
| Current Ratio (MRQ) | 2.03 |
| Operating Cash Flow (TTM) | -118.32 M |
| Levered Free Cash Flow (TTM) | -20.98 M |
| Return on Assets (TTM) | -26.17% |
| Return on Equity (TTM) | -282.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Axsome Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 1.5 |
| Insider Activity | -2.5 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 16.31% |
| % Held by Institutions | 76.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alethea Capital Management, Llc | 31 Dec 2025 | 668,710 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 251.00 (UBS, 15.95%) | Buy |
| Median | 223.50 (3.25%) | |
| Low | 202.00 (Wells Fargo, -6.69%) | Buy |
| Average | 225.00 (3.94%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 170.75 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 24 Feb 2026 | 220.00 (1.63%) | Buy | 169.95 |
| RBC Capital | 24 Feb 2026 | 222.00 (2.55%) | Buy | 169.95 |
| UBS | 24 Feb 2026 | 251.00 (15.95%) | Buy | 169.95 |
| Wells Fargo | 24 Feb 2026 | 202.00 (-6.68%) | Buy | 169.95 |
| Wolfe Research | 24 Feb 2026 | 230.00 (6.25%) | Buy | 169.95 |
| Needham | 23 Feb 2026 | 225.00 (3.94%) | Buy | 174.76 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| JACOBSON MARK L. | - | 223.38 | -4,750 | -1,062,426 |
| Aggregate Net Quantity | -4,750 | |||
| Aggregate Net Value ($) | -1,062,426 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 223.38 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| JACOBSON MARK L. | Officer | 05 May 2026 | Automatic sell (-) | 233 | 223.06 | 51,973 |
| JACOBSON MARK L. | Officer | 05 May 2026 | Option execute | 233 | - | - |
| JACOBSON MARK L. | Officer | 04 May 2026 | Automatic sell (-) | 4,517 | 223.70 | 1,010,453 |
| JACOBSON MARK L. | Officer | 04 May 2026 | Option execute | 4,517 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |